A randomized phase 2 trial in Nature Medicine demonstrates that combining durvalumab immunotherapy with stereotactic radiation produces encouraging clinical responses in early-stage hormone-receptor-positive breast cancer, including patients with PD-L1-negative tumors. — Photo by Logan Gutierrez on Unsplash (Unsplash License)
MD, MPH, PhD. Editor-in-Chief, Georgian Medical Journal (GMJ). Professor and Head, School of Public Health, David Tvildiani Medical University (DTMU), Tbilisi, Georgia. Chair, Public Health Institute of Georgia (PHIG). President, Accréditation Sans Frontières (ASF), Paris. Secretary/Treasurer, UEMS Section of Public Health. WHO Consultant, Health and Migration, Geneva. Former Member, UN Secretary-General's Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (IAP-EWEC, 2016–2021). ORCID: 0000-0001-7609-4515.
